Intensive support recommendations for critically-ill patients with suspected or confirmed COVID-19 infection

Thiago Domingos Corrêa¹, Gustavo Faisal Janot de Matos¹, Bruno de Arruda Bravim¹, Ricardo Luiz Cordioli¹, Alejandra del Pilar Garrido Garrido¹, Murillo Santucci Cesar de Assuncao¹, Carmen Silvia Valente Barbás¹, Karna Tavares Timenetsky¹, Roseny dos Reis Rodrigues¹, Hélio Penna Guimarães¹, Roberto Rabello Filho¹, Frederico Polito Lomar¹, Farah Christina de La Cruz Scarin¹, Carla Luciana Batista¹, Adriano José Pereira¹, João Carlos de Campos Guerra¹, Bárbara Vieira Carneiro¹, Ricardo Kenji Nawa¹, Rodrigo Martins Brandão¹, Antônio Eduardo Pereira Pesaro¹, Moacyr Silva Júnior¹, Fabricio Rodrigues Torres de Carvalho¹, Citlaine Saghabi de Medeiros Silva¹, Ana Claudia Ferraz de Almeida¹, Marcelo Lilaian Pesavento¹, Raquel Afonso Caserta Eid¹, Leonardo José Rolim Ferraz¹
¹ Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

DOI: 10.31744/einstein_journal/2020AE5793

ABSTRACT

In December 2019, a series of patients with severe pneumonia were identified in Wuhan, Hubei province, China, who progressed to severe acute respiratory syndrome and acute respiratory distress syndrome. Subsequently, COVID-19 was attributed to a new betacoronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Approximately 20% of patients diagnosed as COVID-19 develop severe forms of the disease, including acute hypoxemic respiratory failure, severe acute respiratory syndrome, acute respiratory distress syndrome and acute renal failure and require intensive care. There is no randomized controlled clinical trial addressing potential therapies for patients with confirmed COVID-19 infection at the time of publishing these treatment recommendations. Therefore, these recommendations are based predominantly on the opinion of experts (level C of recommendation).

Keywords: Coronavirus; COVID-19; Respiratory insufficiency; Respiratory distress syndrome, adult; Intensive care units

RESUMO


Descritores: Coronavírus; COVID-19; Insuficiência respiratória; Síndrome do desconforto respiratório do adulto; Unidades de terapia intensiva
INTRODUCTION

In December 2019, in Wuhan, province of Hubei, China, many patients developed severe pneumonia and presented severe acute respiratory syndrome (SARS) and acute respiratory distress syndrome (ARDS).\(^1\) Later, the disease disseminated to other regions of China and to many countries in different continents, characterizing a pandemic.\(^3\) The disease was attributed to a new betacoronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\(^4\) The disease caused by this virus was recently named coronavirus disease 2019 (COVID-19).\(^5\)

Patients with COVID-19 present mostly with fever, cough, dyspnea, myalgia, and fatigue.\(^6\) Although most have a favorable progression,\(^2\) approximately 20% develop severe forms of the disease, including acute hypoxemic respiratory failure (AHRF), SARS, ARDS and acute kidney failure (AKF) requiring admission to the intensive care unit (ICU).\(^1\) It has also been found that some groups, especially the elderly and those with other underlying diseases, have greater risk of developing multiple organ dysfunction (MODS) and, ultimately, dying.\(^2\)

As of the publication of these treatment recommendations, no randomized controlled clinical trial (RCT) had yet evaluated potential treatments for patients with confirmed COVID-19 infection.\(^5\) A search on ClinicalTrials.gov\(^10\) using the term “COVID-19” resulted in 179 RCTs in the recruitment phase. A detailed narrative review of the specific treatments used to treat COVID-19 has been published recently.\(^9\)

Therefore, the material provided in these recommendations is based mostly on experts’ opinion. Consequently, they should be considered with caution by healthcare professionals, considering the recommendation level C (case report, including cohort studies or lower quality case-control studies).\(^11\)

CRITERIA FOR ADMISSION TO THE INTENSIVE CARE UNIT

At least one of the following criteria is necessary for admission to the ICU:

- Patients who need supplemental oxygen (nasal cannula – NC \(\text{O}_2 >3.0\text{L/minute}\)) to maintain peripheral oxygen saturation (\(\text{SpO}_2\)) >94% or respiratory rate (RR) ≤24rpm.
- Patients who require non-invasive ventilation (NIV) to maintain \(\text{SpO}_2\) >94% or RR ≤24rpm.
- Acute respiratory failure requiring invasive mechanical ventilation (MV).
- Patients with hemodynamic instability or shock, defined as hypotension (systolic blood pressure - SBP <90mmHg or mean arterial pressure - MAP <65mmHg), or signs of poor organ or peripheral perfusion (changes in consciousness levels, oliguria, lactate ≥36mg/dL, among others), using or not vasopressors.
- Sepsis with hypotension, need for vasopressor or lactate ≥36mg/dL.
- Septic shock according to the Sepsis-3 criteria.\(^12\)

VENTILATORY SUPPORT

Non-invasive ventilation and high-flow nasal cannula:

- The use of NIV in positive airway pressure modalities at two pressure levels (BiPAP) and high flow nasal cannula (HFNC) is contraindicated because of the large production of aerosol.
- A short NIV test (30 minutes) can be conducted for patients with AHFR. The NIV test should be done with maximum parameters of inspired oxygen fraction (\(\text{FiO}_2\)) ≤50%, or positive pressure (PP) with delta ≤10cmH\(_2\)O and expiratory positive airway pressure (EPAP) ≤10cmH\(_2\)O (Figure 1).

Figure 1. Recommendations for the use of non-invasive ventilation in patients with suspected or confirmed COVID-19 infection.
Intensive support recommendations for critically-ill patients with suspected or confirmed COVID-19 infection

- To enable safe use of the NIV interface, a non-vented orofacial mask (without exhalation valve) coupled to a dual circuit, specific for MV and connected to it is recommended.
- Use barrier filter at the expiratory outlet of the mechanical ventilators.
- NIV success criteria: patient tolerates interface and improves respiratory distress (RR <24rpm and SpO₂ ≥94% with FiO₂ ≤50%) after 30 minutes of NIV.
- Definition of NIV dependence: need to remain in NIV greater than or equal to 4 hours over a 6-hour period to maintain RR <24rpm and SpO₂ ≥94%.
- NIV-dependent patients must be transferred to the ICU early, for immediate orotracheal intubation (OTI).

CRITERIA FOR OROTRACHEAL INTUBATION

- Patients who need oxygen supplementation through nasal cannula NO₂C >5L/minute or NIV with FiO₂ >50% or delta PP >10cmH₂O or EPAP >10cmH₂O to maintain SpO₂ >94% or RR ≤24rpm.
- Patients who do not adapt to or do not tolerate the NIV interface.
- NIV-dependent patients.

PROCEDURES FOR OROTRACHEAL INTUBATION

- Team apparel during the OTI procedure: waterproof apron, sterile gloves, N95 mask, hair cap, goggles and face shield.
- Only professionals who will actively participate in the procedure remain in the room. We recommend a trained professional stays by the door of the room for possible support during the OTI.
- Prepare all materials for OTI, including capnograph, drugs, fluids and vasopressors, before beginning the procedure and out of room.
- Vasopressors (norepinephrine) and crystalloids must be prepared and kept ready for infusion before beginning the procedure, due to the potential risk of hypotension after OTI.
- Use orotracheal cannula with subglottic suction and closed suction system in all patients undergoing OTI and MV.
- All OTI procedures must be performed with direct videolaryngoscopy.
- All patients must be intubated with rapid sequence intubation (RSI).
- SpO₂ drop below 70% is a common event immediately after OTI. Therefore, pre-oxygenation (100% O₂) and the proper preparation of both patient and materials to be used for OTI are crucial.
- Avoid ventilation with bag-valve-mask before OTI, due to the increased production of aerosol.
- In patients not using NIV at the time of OTI: pre-oxygenate with reservoir mask at the lowest possible air flow, to maintain effective oxygenation. Avoid assisted ventilation with the bag-valve-mask or use of supraglottic devices, due to the potential aerosol production and team contamination.
- In patients using NIV at the time of OTI: start RSI with the patient in NIV. Remove NIV only to intubate, i.e., do not remove the mask before the OTI.
- Sequence of medications for SRI:
  - Fentanyl 50 to 100mcg, intravenous (IV).
  - Etomidate 0.3mg/kg IV or propofol 2mg/kg IV, at least 2 minutes after fentanyl infusion.
  - Lidocaine 2% without vasoconstrictor 40mg IV.
  - Neuromuscular blockade with succinylcholine 1.0mg/kg IV (or rocuronium 1.2mg/kg IV, if succinylcholine is contraindicated), to facilitate OTI and avoid cough during the procedure.
- After checking the adequate position of the orotracheal tube with the capnograph and installing the heat and moisture exchanger (HME) filter between the tube and the capnograph, the patient may be connect to the ventilator, installing the high efficiency particulate arrestance (HEPA) filter at the expiratory outlet of the ventilator to the environment.

INITIAL ADJUSTMENTS OF THE MECHANICAL VENTILATOR

The following initial MV parameters are recommended immediately after OTI:
- Pressure-controlled volume (PCV).
- Tidal volume (VT) of 6mL/kg of predicted weight.(13)
- Initial positive end-expiratory pressure (PEEP) of 15cmH₂O.
- Respiratory rate between 20 and 24rpm, to maintain minute ventilation (VE) between 7 and 10L/minute.
- Driving pressure (plateau pressure minus PEEP) ≤15cmH₂O.
- Initial SpO₂ targeting between 92 and 96%.
- Initial end-tidal carbon dioxide (EtCO2) targeting between 30 and 45.
- Measuring arterial blood gases 1 hour after OTI is suggested for possible adjustments to the initial MV parameters.
**PROTECTIVE MECHANICAL VENTILATION STRATEGY**

The MV strategy applied for patients with suspected or confirmed diagnosis of COVID-19 is displayed in figure 2.

**CRITERIA TO BEGIN WEANING FROM VENTILATION**

- After 24 hours stable with PEEP initially adjusted according to figure 2, try reducing PEEP by every 1cmH\(_2\)O, every 8 hours, for partial pressure of arterial CO\(_2\) and pH <7.20, evaluate the possibility of reducing PEEP by 2cmH\(_2\)O and reassess.

- If increase in partial pressure of arterial CO\(_2\) and pH <7.20, evaluate the possibility of reducing PEEP by 2cmH\(_2\)O and reassess.

- PEEP mini titration with the PEEP parameters 25cmH\(_2\)O and delta PP 15cmH\(_2\)O for 5 minutes. Optimize sedation and NMB.

- If PEEP mini titration with the PEEP parameters 25cmH\(_2\)O and delta PP 15cmH\(_2\)O for 5 minutes. Optimize sedation and NMB.

- If increase in partial pressure of arterial CO\(_2\) and pH <7.20, evaluate the possibility of reducing PEEP by 2cmH\(_2\)O and reassess.

- PEEP mini titration with the PEEP parameters 25cmH\(_2\)O and delta PP 15cmH\(_2\)O for 5 minutes. Optimize sedation and NMB.

- If PEEP mini titration with the PEEP parameters 25cmH\(_2\)O and delta PP 15cmH\(_2\)O for 5 minutes. Optimize sedation and NMB.

- If increase in partial pressure of arterial CO\(_2\) and pH <7.20, evaluate the possibility of reducing PEEP by 2cmH\(_2\)O and reassess.

- PEEP mini titration with the PEEP parameters 25cmH\(_2\)O and delta PP 15cmH\(_2\)O for 5 minutes. Optimize sedation and NMB.

- If PEEP mini titration with the PEEP parameters 25cmH\(_2\)O and delta PP 15cmH\(_2\)O for 5 minutes. Optimize sedation and NMB.

- If increase in partial pressure of arterial CO\(_2\) and pH <7.20, evaluate the possibility of reducing PEEP by 2cmH\(_2\)O and reassess.

- PEEP mini titration with the PEEP parameters 25cmH\(_2\)O and delta PP 15cmH\(_2\)O for 5 minutes. Optimize sedation and NMB.
arterial oxygen to fraction of inspired oxygen ratio (PaO$_2$/FiO$_2$) >300.
• If the patient is chronically hypoxemic, use PaO$_2$/FiO$_2$ >250 to reduce PEEP.
• Modify the pressure-volume control to spontaneous only when PEEP ≤15cmH$_2$O, FiO$_2$ <50%, and Richmond agitation-sedation scale (RASS) >-5.(14)

**CRITERIA TO BEGIN SPONTANEOUS BREATHING TRIAL**

To conduct the spontaneous breathing trial (SBT) we recommend the patient should (Figures 3 and 4):
• Remain for 24 hours in pressure support ventilation (PSV) with PEEP=10cmH$_2$O, FiO$_2$ <40% and support pressure (SP) ≤10cmH$_2$O, and maintain airway occlusion pressure for the first 100 milliseconds (P0.1) ≤4cmH$_2$O.
• Present adequate level of consciousness: RASS 0-2(14) or close to baseline.
• Be hemodynamically stable, defined by no need for vasopressors or <0.2mcg/kg/minute norepinephrine or dobutamine stable dose or weaning, and appropriate tissue perfusion marker levels.
• After 24 hours with the MV parameters as described above and adequate gas exchange, characterized by pH 7.3 with arterial pressure of carbon dioxide (PaCO$_2$) <55mmHg; PaO$_2$ ≥60mmHg with FiO$_2$ ≤40%; PEEP ≤10cmH$_2$O; PaO$_2$/FiO$_2$ ≥250; SpO$_2$ ≥90%, start SBT (Figures 3 and 4).
• Do not perform cuff leak test(15) before extubating patients due to the risk of aerosol production.

**ANALGESIA ANDSEDATION**

• The association between propofol (maximum dose of 3.0mg/kg/hour) IV and fentanyl (25 to 50mcg/hour; maximum dose 100mcg/hour) IV is the first choice for sedation and analgesia in patients on MV due to COVID-19.
• If the propofol dose is greater than 3mg/kg/hour, it should be combined with midazolam, at a dose of 0.02 to 0.2mg/kg/hour, IV.
• Recommended sedation targeting during the first 48 hours of MV: RASS -5.

---

**Figure 3.** Flowchart for weaning from mechanical ventilation in patients with suspected or confirmed diagnosis of COVID-19

**Recommended sedation targeting after the first 48 hours of MV:**
- \( \text{PaO}_2/\text{FiO}_2 \leq 250 \) and PEEP \( \leq 15\text{cmH}_2\text{O} \), and \( \text{FiO}_2 \leq 50\% \): RASS -3 to zero.
- \( \text{PaO}_2/\text{FiO}_2 \leq 250 \) and/or PEEP \( \geq 15\text{cmH}_2\text{O} \): RASS -4 to -5.

**If required, additional doses to control agitation during MV should be given:**
- Propofol: 10 to 40mg IV bolus.
- Midazolam: 3 to 5mg IV bolus.
- For additional pain control (analgesia) during MV, additional IV bolus of fentanyl should be given (50mcg IV) and association with regular analgesics (e.g. dipyrrone or paracetamol) to spare using opioids.

**Regarding the use of neuromuscular blockers (NMB), administering cisatracurium 0.15mg/kg IV bolus is recommended, followed by infusion of 1 to 4mcg/kg/minute in continuous infusion pump (CIP), when one of the following is observed:**
- Persistent severe asynchrony characterized by worsening of oxygenation and ventilation after adjusting MV and sedation, in patients with \( \text{PaO}_2/\text{FiO}_2 \) between 150 and 200;
- \( \text{PaO}_2/\text{FiO}_2 < 150 \) with PEEP \( > 15\text{cmH}_2\text{O} \).

**In patients on NMB, based on current guidelines,**\(^{(16,17)}\) we recommend:
- Bi-spectral index (BIS) targeting 40 to 60, with burst suppression rate (SR) > zero.
- Train of four (TOF): targeting zero (assess once a day, if possible).
- When BIS monitoring is not possible, deep sedation should be given (RASS-5) before beginning NMB infusion.

**We suggest maintaining NMB for 48 hours after starting it for COVID-19 patients. Patients on NMB for more than 48 hours, if \( \text{PaO}_2/\text{FiO}_2 > 200 \) and PEEP \( < 20\text{cmH}_2\text{O} \), stop NMB and reassess in 24 hours.

**For patients in continuous sedation, daily revision of the possibility of decreasing sedation is recommended if pH > 7.30 and:**
- If \( \text{PaO}_2/\text{FiO}_2 > 200 \), try replacing midazolam with propofol, if midazolam is being used.
- If \( \text{PaO}_2/\text{FiO}_2 > 300 \), try replacing propofol with dexmedetomidine (0.3 to 1.3mcg/kg/hour).
- Concurrently try to gradually reduce the dose of fentanyl.

**During the attempt to decrease sedation, if the patient presents asynchrony with drop in SpO\(_2\) and/or hemodynamic instability, we suggest:**
- Administer 10 to 40mg propofol IV bolus and 25 to 50mcg fentanyl IV bolus.
- Administer one dose of neuroleptics (Quetiapine 25 to 50mg via nasoenteral tube – NET – or, if not possible, use haloperidol IV).
- If there is no improvement after 20 minutes, deepen the sedation, decreasing by -2 in the RASS, or as far as RASS-5, and reevaluate within 24 hours. If two or more boluses are needed in a 6-hour period, consider deepening sedation and reassessing within 24 hours.
- After 48-hour sedation, in patients chronically using psychoactive drugs, reconcile before considering the reduction of continuous sedation.

---

\(^{*}\) If patient presents contraindication to NIV, keep in 100% bag-mask and check often. Keep NIV for 18 hours after extubation. After this period, if the patient is unable to stay 2 hours with no NIV or OTI.

**SBT:** spontaneous breathing trial; OTI: orotracheal intubation; CIP: intravenous route; UAW: upper airway; 100% bag-mask: oxygen reservoir mask (non-rebreather); NIV: non-invasive ventilation.

**Figure 4.** Flowchart of care after spontaneous breathing trial and extubation of patients with suspected or confirmed diagnosis of COVID-19
### GENERAL MEDICAL SUPPORT

- Hand hygiene always. Install contact and aerosol precautions during the entire ICU stay.
- Avoid drugs that prolong the QT interval (example: zofran, bromopride, fluconazole, metoclopramide, antiarrhythmic drugs), especially if using macrolides or chloroquine.
- Do not provide inhalation therapy, so as to avoid aerosol production. Use bronchodilators with spacer in case of bronchospasm.

### ANTIBIOTIC THERAPY

- Empiric use of antibiotics is recommended for patients who progress to SARS or septic shock associated to COVID-19, as follows:
  - Initial empiric treatment for cases with no hypoxemia documented:
    - Oseltamivir 75mg *per os* (PO) or via NET bid, for 5 days. Wait for the result of the viral panel before interrupting the drug before the fifth day.
  - Initial empiric treatment of cases with documented hypoxemia:
    - Oseltamivir as above;
    - Ceftriaxone 1g, bid, IV, for 7 days in association with azithromycin 500mg PO or NET once a day, for 5 days. If infection by methicillin-resistant *Staphylococcus aureus* (MRSA) is suspected, ceftaroline 600mg bid, IV, for 7 days (or another antibiotic with broader coverage for Gram-negative bacteria, in case of suspected multidrug-resistant bacteria) in association with azithromycin 500mg PO or NET once daily, for 5 days.

### HEMODYNAMIC SUPPORT

The algorithm for hemodynamic support of patients with COVID-19 is depicted in figure 5.

- Invasive blood pressure (IBP) monitoring is suggested, as well as the insertion of a central venous catheter (CVC) in patients receiving norepinephrine at a dose >0.1mcg/kg/minute and increasing.
- Avoid using a peripherally inserted central catheter (PICC) to administer norepinephrine or maintain venous access, due to the increased risk of thrombotic events.
- If norepinephrine >0.5mcg/kg/minute, starting epinephrine 0.01mcg/kg/minute is suggested.

- The administration of hydrocortisone 200mg IV in CIP is recommended if norepinephrine >0.2mcg/kg/minute after 6 hours of resuscitation.

### PROPHYLAXIS

- Prophylaxis for stress ulcer: pantoprazole 40mg IV once a day.
- Prophylaxis for deep venous thrombosis (DVT):
  - Pneumatic compression (with no elastic stockings);
  - Initiate 5,000IU unfractionated heparin subcutaneous (SC), tid, for every patient, except when absolutely contraindicated.
D-dimer value will not change management for venous thromboembolism (VTE) prophylaxis with medication.

**ANTICOAGULATION**

- Do not use full anticoagulation based on the isolated D-dimer value.
- Indicate full anticoagulation only when confirmed thromboembolic event or with formal indication – e.g. chronic atrial fibrillation.

**USE OF STEROIDS**

- If patient present septic shock, administer 200mg hydrocortisone IV via CIP, every 24 hours, as previously described (Figure 5).
- If patient progresses to need for MV and is not on hydrocortisone due to septic shock, initiate methylprednisolone 0.5mg/kg/day IV, for 7 days.
- Corticosteroid withdrawal: begin after 7 full days of treatment. Reduction to 50% of the dose in D8 and to 25% of the dose in D9.

**GLYCEMIC CONTROL**

- Capillary blood glucose every 6 or 4 hours, according to the glycemic control protocol of the organization.
- Avoid using insulin in CIP, to minimize exposure of the care team. Administer long-acting insulin early according to glycemic control of the previous 24 hours. However, if patient is receiving norepinephrine >0.2mcg/kg/minute, avoid administering SC insulin.

**SPECIFIC DRUGS FOR TREATING COVID-19**

- Hydroxychloroquine: 400mg NET, bid, for 10 days is recommended. Do baseline and serial electrocardiogram (ECG) to check the QT interval. If corrected QT >500ms (or increment >60ms), re-evaluate risk-benefit, discontinue all additional drugs that prolong QT, including azithromycin. Maintain serum potassium levels >4.0mEq/L and magnesium >2.0mEq/L.
- Macrolides: azithromycin 500mg per day via NET, for 10 days, or clarithromycin 500mg IV, every 12 hours is recommended, if a patient is using a vasoactive drug. Especially in cases of concurrent use with hydroxychloroquine, ions and prolonged QT interval (corrected QT) should be monitored.
- Tocilizumab: its use is suggested only in selected cases, such as in patients with serum interleukin 6 (IL-6) level ten-fold above the upper normal limit or more, elevated D-dimer, thromboelastometry suggestive of hypercoagulability state and sequential organ failure assessment (SOFA) score ≥4, in addition to no presumed secondary bacterial infection, or liver dysfunction (international normalized ratio – INR >2.0 or total bilirubin – TB >2.0). Liver function should be monitored. The dose should be 4 to 8mg/kg (maximum unit dose: 800mg), with a maximum of three doses, every 12 hours.
  - The use of lopinavir + ritonavir, remdesivir, convalescent serum, nitazoxanide, ivermectin and arbidol is restricted to clinical research protocols.

**ADDITIONAL TESTS**

- The following laboratory tests should be sampled on daily basis during the ICU stay: complete blood count; kidney function (creatinine - Cr - and urea - Ur); electrolytes including sodium, potassium, magnesium, ionized calcium and phosphorus; arterial blood gases and lactate (if in hypoxemic MV and/or shock) and/or central venous blood gas (if with no IBP, or if weaning from MV, or not on MV and without hypoxemia and without shock) and C-reactive protein (CRP).
- If secondary bacterial infection is suspected, collect cultures and serial measurements of CRP and procalcitonin (PCT).
- Collect D-dimer every 48 hours (acts as a severity marker).
- Chest X-ray in case of clinical deterioration and always after procedures (OTI, CVC introduction, etc.).
- Consider daily ECG if the patient is using macrolides and hydroxychloroquine.
- Upon admission to ICU, collecting the daily tests described above, as well as troponin, type B natriuretic peptide (BNP), liver function, lactic dehydrogenase (DHL), ferritin, D-dimer, prothrombin time (PT), INR, activated partial thromboplastin time (aPTT), fibrinogen, thromboelastography, PCT, cultures, ECG and chest X-ray is recommended. Transthoracic echocardiography should be carried out within the first 24 hours of ICU admission.

**CONCLUSION**

The clinical management of patients diagnosed with COVID-19 who develop severe forms of the disease and require intensive care is complex. Due to the complexity of patients, the exponential growth of new cases, and the
high demand for supplies, human resources and trained professionals, critically-ill patients with COVID-19 are a major challenge for care teams and health systems. The evidence available in the literature for the treatment of patients with COVID-19 is scarce and limited to non-controlled studies. The recommendations presented in this document were developed to guide healthcare professionals who are directly involved in the care of COVID-19 patients, although predominantly based on experts’ opinions. Robust evidence from randomized controlled trials is required so that COVID-19 patients can be provided with more effective and safer treatments.

### Authors’ Information

Corrêa TD: http://orcid.org/0000-0001-5946-3910  
Matos GF: http://orcid.org/0000-0001-9996-7040  
Bravim BA: http://orcid.org/0000-0001-8290-8554  
Cordioli RL: http://orcid.org/0000-0001-7521-399X  
Garrido AG: http://orcid.org/0000-0002-2469-185X  
Assuncão MS: http://orcid.org/0000-0002-0741-4869  
Barbas CS: http://orcid.org/0000-0002-3922-6256  
Timenetsky KT: http://orcid.org/0000-0002-4176-2445  
Rodrigues RR: http://orcid.org/0000-0002-3796-5952  
Guimarães HP: http://orcid.org/0000-0001-5523-1015  
Rabelo Filho R: http://orcid.org/0000-0001-7018-224X  
Lomar FP: http://orcid.org/0000-0002-7856-0716  
Scarin FC: http://orcid.org/0000-0001-5724-6448  
Batista CL: http://orcid.org/0000-0001-8628-0792  
Pereira AJ: http://orcid.org/0000-0002-9467-6516  
Guerra JC: http://orcid.org/0000-0002-4156-529X  
Nawa RK: http://orcid.org/0000-0002-0852-7013  
Brandão RM: http://orcid.org/0000-0003-1442-9097  
Pesaro AE: http://orcid.org/0000-0003-3133-4989  
Silva Júnior M: http://orcid.org/0000-0002-6479-1708  
Carvalho FR: http://orcid.org/0000-0001-8712-269X  
Silva CS: http://orcid.org/0000-0003-3544-6646  
Almeida AC: http://orcid.org/0000-0002-5339-0415  
Franken M: http://orcid.org/0000-0002-4286-8559  
Pesaro AE: http://orcid.org/0000-0001-5739-8208  
Eid RA: http://orcid.org/0000-0002-8241-3241  
Ferraz LJ: http://orcid.org/0000-0003-1822-1568

### References